AstraZeneca Pharma India Limited has announced a robust 33% year-on-year growth in total revenue for the financial year 2025-26, reaching ₹22,755.8 million. This significant increase underscores the company’s strong performance across its therapy areas and its commitment to delivering innovative medicines to patients in India.
The financial year was marked by the achievement of 11 regulatory approvals for new medicines and indications, reinforcing AstraZeneca’s leadership in various therapy areas. The company’s revenue from operations for the fourth quarter of the fiscal year stood at ₹5,786.1 million, while profit before exceptional items and tax was ₹592.2 million. Profit after exceptional items and tax for the full fiscal year was ₹1,875.2 million.
AstraZeneca’s Oncology segment contributed ₹16,100.9 million to the total revenue, while the Biopharmaceuticals segment, which includes Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Vaccines & Immune Therapies (V&I), added ₹5,243.2 million. The Rare Disease segment accounted for ₹214.6 million.
The company achieved several key milestones during the year, including regulatory approvals for Durvalumab in endometrial and muscle invasive bladder cancer, Eculizumab for rare diseases, and Osimertinib for non-small cell lung cancer (NSCLC). Other significant approvals included Trastuzumab deruxtecan for HER2-low metastatic breast cancer and Benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA).
AstraZeneca also received recognition for its achievements, being named Pharma Company of the Year at the ET RePharma Awards and receiving the Medical Excellence Award for Rare Disease at OPPI India. The company was also recognised as a Top Employer in India for 2025.
Bhavana Agrawal, Chief Financial Officer & Director of AstraZeneca India, highlighted the strong and consistent growth, attributing it to the resilience of the business and the strength of the company’s science-led portfolio. Praveen Rao Akkinepally, Managing Director, emphasised the company’s focus on transforming patient outcomes through science-led innovation.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).